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OBJECTIVES We examined whether unloading of the left ventricle with a ventricular assist device (LVAD)
can result in normalization of the creatine kinase (CK) abnormalities in the failing human
heart.
BACKGROUND Left ventricular failure is associated with a decrease of myocardial total CK activity and a fetal
shift in CK isoform expression that results in an increase in the cytosolic brain type
homodimeric-creatine kinase (CK-B) subunit and decreases of the cytosolic muscle-creatine
kinase (CK-M) and CK-mitochondrial (CK-Mt) isoforms. The mechanisms of this
abnormality are not known.
METHODS Total CK activity and CK protein isoform expression (Western blotting) were examined in
11 patients with end-stage cardiomyopathy. In 7 patients, myocardial tissue was also obtained
after 4.1  1.1 months of left ventricular assist device (LVAD) support.
RESULTS Left ventricular unloading produced by LVAD implantation resulted in a 270%  114%
increase in total CK activity (p  0.01) that was associated with a 69%  18% increase in
CK-M protein expression (p  0.01) and a 121%  69% increase in CK-Mt protein
expression (p  0.01), but no significant change in CK-B expression.
CONCLUSIONS Systolic and diastolic unloading provided by the LVAD resulted in increases of total CK
activity as well as CK-Mt and CK-M protein expression. The failure of CK-B expression to
decrease suggests that abnormalities other than increased loading are responsible for the
increase in CK-B expression in the failing heart. (J Am Coll Cardiol 2002;39:1773–9)
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In the heart adenosine triphosphate (ATP) is mainly syn-
thesized in the mitochondria through oxidative phosphor-
ylation and transported to the contractile apparatus, where it
is consumed by myosin ATPase to generate force. In the
normal heart, the creatine kinase (CK) system appears to
facilitate ATP production, transport and utilization (1,2).
Creatine kinase catalyzes the near-equilibrium reaction,
transferring a phosphoryl group between ATP and creatine
without loss of free energy: phosphocreatine (PCr) 
magnesium (Mg) adenosine 5-diphosphate (ADP)  H
7 creatine  Mg ATP. Creatine kinase consists of two
subunits, cytosolic muscle-creatine kinase (CK-M) and
cytosolic brain type homodimeric-creatine kinase (CK-B),
resulting in three dimeric isoenzymes that are found in the
cytosol: MM, MB and BB (3). The CK-MM isoenzyme is
localized to the thick filaments of the contractile apparatus,
where ADP generated by myosin ATPase during contrac-
tion can be rapidly rephosphorylated (4). CK-B is present
mainly in fetal myocardium and is normally found only in
trace amounts in the adult heart (5). A fourth isoform,
CK-mitochondrial (CK-Mt), is found on the inner mito-
chondrial membrane in association with adenine nucleotide
translocase; by transferring a phosphoryl group from ATP
to creatine to form PCr, CK-Mt increases ADP availability
to the ATP synthase (6). In failing hearts, a fetal shift in CK
isoform expression occurs with an increase in the CK-B
containing isoform and decreases in CK-MM (3,7–9),
CK-Mt and total CK activity. It has been postulated that
the fetal shift in CK enzyme expression is stimulated by a
sustained increase in wall stress (3) and that it can be
attenuated or reversed by pharmacologic unloading of the
left ventricle (8,10,11).
Left ventricular assist devices (LVAD) are currently being
used as bridge-to-transplant therapy in patients with severe
heart failure (12,13). This provides the opportunity to
determine whether the marked systolic and diastolic un-
loading of the dysfunctional left ventricle (LV) provided by
this device can result in normalization of the CK abnormal-
ities in the failing human heart. We observed that in
response to unloading with the LVAD, total CK activity,
CK-M and CK-Mt protein expression increased markedly.
However, CK-B expression failed to decrease, suggesting
that this abnormality is not merely the result of abnormally
increased LV wall stress.
MATERIALS AND METHODS
Patient selection. Eleven patients (mean age 50 years;
range 27 to 61 years) with end-stage idiopathic/ischemic
cardiomyopathy and no other end organ failure were stud-
ied. Mean LV ejection fraction was 18% before LVAD
implantation. Of the 11 patients who had LVAD implan-
tation, specimens were also available from seven of the
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patients who subsequently underwent heart transplantation.
Pre-LVAD myocardial specimens were obtained during
LVAD implantation from the apex of the LV at the
location of the LVAD inflow cannula. Post-LVAD myo-
cardial specimens were collected from the left ventricle at
heart transplantation. Samples were immediately frozen in
liquid nitrogen and stored at 80°C.
Protein extraction and Western blot analysis. For protein
extraction, frozen myocardial samples (50mg) were ho-
mogenized in 1 ml of ice-cold buffer (0.2 M potassium
phosphate, pH 7.4, 5 mM ethylene glycol-bis(2-
aminoethylether)-NNNN-tetraacetic acid, 5 mM beta-
mercaptoethanol and 10% [v/v] glycerol) to release mito-
chondrial and cytoplasmic enzymes (7), incubated for 1 h
with gentle agitation at 4°C and centrifuged such that the
resultant supernatant contained the CK isoenzymes in an
optimal yield. Protein concentration was determined by a
modified Lowry method (Sigma Diagnostics, Dorset,
United Kingdom). Supernatants were electrophoresed on
12% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) using the Protean Electrophoresis
apparatus (BioRad, Hercules, California) (14). Commer-
cially prepared molecular weight standards and purified
proteins (CK-MM, CK-MB, CK-BB all obtained from
Aalto Bio Reagents, Dublin, Ireland) were run as controls.
The protein subunits were transferred to a nitrocellulose
membrane and incubated with primary antibody (1:3,000
dilution in Tween-Tris-buffered saline; 0.1% Tween-20,
20 mM Tris base, 137 mM NaCl, pH 7.6) for 2 h.
Monoclonal mouse antibodies specific to CK-M and CK-B
(OEM Concepts Inc., Toms River, New Jersey) were
directed against their respective protein subunits bound to
the membrane. A rabbit polyclonal antibody specific for
CK-Mt subunit (from A. W. Strauss, Washington Univer-
sity) was used at a dilution of 1:2,000. Membranes were
washed and incubated with the appropriate secondary
horseradish peroxidase-labeled (antimouse or antirabbit)
immunoglobulin G antibody, incubated for 1 min with the
chemiluminescent substrate (ECL, Amersham, Bucking-
hamshire, United Kingdom) and exposed to X-ray film for
15 s to 10 min. Membranes were stripped and sequentially
reprobed. Densitometry was used for relative quantitation of
the CK protein subunits normalized to beta-actin.
Total CK and CK activity. Total CK activity (IU/mg
protein) was measured using a Cal Biochem CK-nac re-
agent kit (Sigma) (15). Homogenate activities in excess of
1,000 U/l were diluted so that total activity did not exceed
the linearity of the system.
Statistical analysis. Data from the pre-LVAD and post-
LVAD specimens were analyzed using the two-tailed un-
paired t test and the paired t test, with the level of
significance set at 0.05. All results are reported as mean 
SEM.
RESULTS
Patient characteristics. The clinical characteristics of the
11 patients are summarized in Table 1. All patients were
New York Heart Association functional class IV at LVAD
implantation.
Western blot analysis. Representative Western blots of
CK-M, CK-B and CK-Mt demonstrated migrations to
positions corresponding to 40 to 45 kd on 12% SDS-
polyacrylamide gel (Fig. 1). Densitometry of the protein
levels normalized to beta-actin showed a mean CK-M
subunit value of 1.18  0.12 pre-LVAD (n  11) and
Abbreviations and Acronyms
ADP  adenosine 5-diphosphate
ATP  adenosine triphosphate
CK  creatine kinase
CK-Mt  creatine kinase-mitochondrial
LV  left ventricle
LVAD  left ventricular assist device
Mg  magnesium
PCr  phosphocreatine
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
Table 1. Clinical Characteristics of Patients With End-Stage Dilated or
Ischemic Cardiomyopathy
Patient Diagnosis
Age
(yrs)
EF
(%)
CO
(l/min)
HR
(beats/min)
SBP
(mm Hg)
DBP
(mm Hg)
A ischemic 59 20 4.8 113 88 63
B DCM 52 15 3.1 95 89 47
C ischemic 61 15 2.7 105 97 46
D ischemic 45 20 4.4 112 105 70
E ischemic 51 35 7.3 79 99 45
F DCM 45 15 6.7 105 80 46
G ischemic 52 15 3.0 80 91 51
H DCM 54 15 4.7 100 97 43
I DCM 52 20 4.0 94 85 50
J DCM 27 10 6.9 110 102 76
K DCM 51 21 3.9 90 119 64
Mean  SEM 49  2.7 18  1.9 4.7  0.48 99  3.6 96  3.3 55  3.5
CO  cardiac output; DBP  diastolic blood pressure (cuff); DCM  dilated cardiomyopathy; EF  ejection fraction; HR 
heart rate; SBP  systolic blood pressure (cuff).
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Figure 1. Densitometric intensities for protein bands from Western blots of creatine kinase (CK)-M, CK-B and creatine kinase-mitochondrial (CK-Mt)
isoforms normalized to beta-actin. A through F represents six individual patients before and after left ventricular assist device (LVAD) implantation. The
protein levels of CK-M and CK-Mt isoforms were increased after LVAD implantation while CK-B and beta-actin were unchanged.
Figure 2. Densitometric intensities for protein bands from Western blots of creatine kinase (CK)-M (A), CK-B (B) and creatine kinase-mitochondrial
(CK-Mt) (C) isoforms normalized to beta-actin. The ratio of CK-M and CK-Mt to beta-actin increased significantly after hemodynamic unloading
provided by the left ventricular assist device (LVAD). Values are mean  SEM. *p  0.05 versus pre-LVAD. Black bars  pre-LVAD; white bar 
post-LVAD.
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1.85  0.17 post-LVAD (p  0.01; n  7) (Fig. 2). The
normalized CK-Mt protein expression level was 1.31 
0.27 pre-LVAD (p  0.05) and 2.01  0.16 post-LVAD
(p  0.05). CK-B expression was not different pre-LVAD
(2.02  0.31) and post-LVAD (2.24  0.30). In the paired
analysis of seven patients from whom samples were available
both pre- and post-LVAD implantation, CK-M subunit
expression was increased by 59% (Fig. 3; 1.16  0.15 vs.
1.85  0.17, p  0.01), CK-Mt protein expression was
increased by 53% (Fig. 3; 1.31  0.26 vs. 2.01  0.16, p 
0.01), whereas CK-B subunit expression was not signifi-
cantly changed.
Myocardial total CK activity. Chemically measured total
CK activity normalized to cardiac protein for all 11 patients
was 6.2 1.13 IU/mg pre-LVAD and 14.37 2.56 IU/mg
post-LVAD (p  0.01). In the paired analysis of the
seven patients from whom myocardial specimens were
available both pre-LVAD and post-LVAD, total CK
activity increased by 185% following LVAD implantation
(from 5.1  1.42 to 14.4  2.56 IU/mg protein, p  0.01)
(Fig. 3).
DISCUSSION
CK activity in normal and failing hearts. An altered
expression of CK protein and activity is observed in failing
hearts (16). Although normal myocardial tissue was not
available in the present study, several investigators have
previously reported CK activity and isoform distribution in
normal human hearts. Nascimben et al. (7) reported total
Figure 3. CK-M protein normalized to beta-actin before and after left ventricular assist device (LVAD) implantation in patients with heart failure (A).
Creatine kinase-mitochondrial (CK-Mt) normalized to beta-actin before and after LVAD implantation in patients with heart failure (B).
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CK activity of 11.6  2.4 IU/mg protein in surgical and
autopsy specimens from patients without known cardiac
disease. In that study CK activity was decreased to 7.7 1.9
IU/mg protein in patients with dilated cardiomyopathy
undergoing cardiac transplantation. This value is similar to
the total CK activity of 6.2  1.1 IU/mg protein in the
patients undergoing LVAD implantation in the present
study. Bristow et al. (17) reported that total CK activity was
22% lower in LV tissue obtained from hearts removed at
cardiac transplantation than that from nonfailing myocar-
dium obtained from brain-dead organ donors. Sylven et al.
(18) found that CK activity in the LV of failing hearts was
44% lower than in control hearts. Interestingly, Nascimben
et al. (7) reported that total CK activity was significantly
lower in donor hearts than in myocardium obtained from
accident victims, suggesting that subjects maintained on life
support have a decrease of total CK activity. In the present
study CK activity increased from 6.2 IU/mg in failing hearts
to 14.4 IU/mg in the post-LVAD group, indicating that
unloading of the left ventricle is associated with restoration
of total CK activity toward normal.
CK isoform expression. Concomitant with the decrease in
total CK activity, LV overload or failure is associated with a
fetal shift in CK isoform expression (16). Thus, in patients
with dilated cardiomyopathy, Nascimben (7) reported that
CK-MB was increased from 2.4  4% of total CK to 27 
6%; CK-MM was decreased from 88  6% to 63% of total
CK, while CK-Mt was unchanged at 9% to 10% of total
CK. Similarly, animal models of LV pressure overload
resulting from aortic stenosis or volume overload secondary
Figure 3. (Continued) CK-B normalized to beta-actin before and after LVAD implantation in patients with heart failure (C). Total CK activity per mg
cardiac protein before and after LVAD implantation in patients with heart failure (D). Data are from seven hearts in which both pre- and post-LVAD
specimens were available. Each symbol represents the specimens from the same heart.
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to mitral regurgitation demonstrate marked increases in
CK-B protein expression (10,19,20). In comparison with
myocardium from organ donors, papillary muscle specimens
obtained from patients undergoing surgery for mitral regur-
gitation demonstrated no difference in total CK activity or
CK-M activity, but CK-Mt was 40% lower and CK-B was
15- to 20-fold higher than in the normal hearts (18). These
investigators suggested that a reciprocal relationship might
exist between the CK-B and CK-Mt isoforms. However, in
a study of mice lacking genes for either CK-M or CK-Mt,
Saupe et al. (21) demonstrated that loss of either CK-M or
CK-Mt had no effect on CK-B protein expression. These
investigators also observed that the intrinsic activities of
CK-BB and CK-MM isoenzymes were equivalent, suggest-
ing that the isoenzyme shift toward the fetal pattern in the
failing hearts confers no kinetic advantage (21).
Effect of ventricular unloading. Several investigators have
examined CK isoform distribution following pharmacologic
vasodilator therapy in overloaded or failing hearts. Schultz
et al. (20) reported that in dogs with chronic volume
overload due to mitral regurgitation, treatment with the
angiotensin-converting enzyme inhibitor ramipril resulted
in normalization of left ventricular filling pressure, but did
not decrease CK-B gene or protein expression. Similarly,
Pauletto et al. (22) demonstrated that captopril treatment of
rats with renovascular hypertension reduced blood pressure
and normalized left ventricular mass, but did not reverse the
increased expression of CK-MB. In contrast, in studies of
pressure overload hypertrophy using the two-kidney-one-
clip rat hypertension model, normalization of blood pressure
with hydralazine did reverse the CK isoform switch despite
persistent hypertrophy (10). Left ventricular unloading is
much greater with LVAD placement than with pharmaco-
logic therapy. As with drug therapy, there is also a tendency
to normalize neurohormonal and reflex activity following
LVAD placement so that it is difficult to separate the direct
effects of mechanical unloading from the neurohormonal
alterations following LVAD placement. In the present
study LVAD placement caused prominent increases of both
CK-M and CK-Mt subunit expression as well as CK total
activity. However, CK-B did not decrease. The reason for
the persistently elevated CK-B expression is unclear. Nev-
ertheless, from a functional point of view the prominent
increases of CK-M and CK-Mt, as well as total CK activity,
would be expected to restore CK kinetics toward normal. It
is of interest that the 1.6-fold increase in CK-M and the
1.54-fold increase in CK-Mt protein expression were asso-
ciated with a more than doubling of CK activity. The reason
for this apparent discrepancy between protein expression
and activity is uncertain, but may be in part related to the
faster kinetics of CK-Mt.
Although the increased systolic wall stress of the dilated,
failing left ventricle might be expected to increase energy
consumption, several investigators have reported that coro-
nary blood flow and myocardial oxygen consumption are
decreased in the failing heart (23). In support of this
finding, studies of isolated muscle strips from failing human
hearts demonstrated reduced heat liberation by both
tension-dependent (actin-myosin cross-bridging) and
tension-independent (calcium cycling) mechanisms, sug-
gesting downregulation of energy utilization processes (24).
Other enzyme systems involved in energy production in-
cluding the mitochondrial F0,F1-ATPase are also decreased
in the failing heart (25). These findings might suggest that
the decreases of CK-M and CK-Mt are also a response to
decreased energy-utilizing processes in the failing heart. If
this were the case, however, then the marked reduction of
systolic work resulting from LVAD implantation would
have been expected to cause a further decrease of CK-M
and CK-Mt as a result of the decrease in myocardial ATP
demand. In fact, the opposite occurred. Unloading of the
ventricle was associated with increases of both CK-M and
CK-Mt to levels similar to those reported in normal hearts
(7). These findings indicate that the decreases of CK-M and
CK-Mt in the failing heart are not merely responses to a
decrease of energy utilization processes, but likely represent
a more fundamental alteration of protein expression in the
failing heart.
Functional implications of CK alterations. A critical
question is whether the abnormalities of the CK system
have the potential to contribute to contractile dysfunction in
the failing heart. The CK system is thought to optimize
myocardial energy metabolism by maintaining ADP levels
high at the mitochondria where ATP is generated and low
at sites of ATP utilization, thereby contributing to mainte-
nance of a high free energy for ATP hydrolysis to enhance
the efficiency of contraction (1). Acutely inhibiting CK
activity with iodacetamide or replacing myocardial creatine
by feeding with poorly hydrolyzable creatine analog impair
the maximal cardiac workloads that can be achieved in
response to catecholamine stimulation or increased perfus-
ate calcium (26,27). Hearts from mice lacking genes for
either CK-M or both CK-M and CK-Mt perform normally
during basal conditions but may have impairment of max-
imal contractile performance, and require increased cytoso-
lic free ADP levels to achieve any given level of contractile
work (21,28). Nevertheless, even during severe reductions of
CK activity, contractile performance appears to be impaired
only at very high cardiac workloads. Furthermore, Roman et
al. (29) have demonstrated in mouse skeletal muscle that
there is functional equivalence of the CK isoforms, so that
the alteration of isoform expression in the patients with
heart failure would not be expected to have a substantial
effect on cardiac contractile performance. Because CK flux
in the normal heart is at least an order of magnitude faster
than the rate of ATP synthesis, the moderate reductions of
total CK activity in the failing hearts would not be expected
to result in myocardial dysfunction (30,31). Thus, it is not
clear whether the marked decrease of CK activity in the
cardiomyopathic hearts contributed to the development of
cardiac failure.
In conclusion, the systolic and diastolic unloading pro-
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vided by the LVAD resulted in increases of CK-M and
CK-Mt protein expression that were associated with in-
creases of total CK activity. These changes would be
expected to facilitate intracellular phosphoryl transfer from
sites of energy production to sites of energy utilization, and
to allow maintenance of lower cytosolic free ADP levels at
any level of oxygen utilization. Whether these changes in
response to mechanical unloading have the potential to
improve contractile performance in the failing myocardium
will require further study.
Reprint requests and correspondence: Dr. Jianyi Zhang, Car-
diovascular Division, Department of Medicine, University of
Minnesota Medical School, Mayo Mail Code 508, 420 Delaware
Street SE, Minneapolis, Minnesota 55455. E-mail: zhang047@
tc.umn.edu.
REFERENCES
1. Wyss M, Smeitink J, Wevers RA, Wallimann T. Mitochondrial
creatine kinase: a key enzyme of aerobic energy metabolism. Biochim
Biophys Acta 1992;1102:119–66.
2. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy
shuttle. Ann Rev Biochem 1985;54:831–62.
3. Ingwall JS. Is cardiac failure a consequence of decreased energy
reserve? Circulation 1993;87 Suppl VII:VII58–62.
4. Ventura-Clapier R, Saks VA, Vassort G, Lauer C, Elizarova GV.
Reversible MM-creatine kinase binding to cardiac myofibrils. Am J
Physiol 1987;253:C444–55 (Cell Physiol 22).
5. Trask RV, Billadello JJ. Tissue-specific distribution and developmental
regulation of M and B creatine kinase mRNAs. Biochim Biophys Acta
1990;1049:182–8.
6. Saks VA, Khuchua ZA, Vasilyeva EV, Belikova O, Kuznetsov AV.
Metabolic compartmentation and substrate channelling in muscle
cells: Role of coupled creatine kinases in in vivo regulation of cellular
respiration—a synthesis. Mol Cell Biochem 1994;133:155–92.
7. Nascimben L, Ingwall JS, Pauletto P, et al. Creatine kinase system in
failing and nonfailing human myocardium. Circulation 1996;94:1894–
901.
8. Nascimben L, Friedrich J, Liao R, Pauletto P, Pessina AC, Ingwall JS.
Enalapril treatment increases cardiac performance and energy reserve
via the creatine kinase reaction in myocardium of Syrian myopathic
hamsters with advanced heart failure. Circulation 1995;91:1824–33.
9. Khuchua ZA, Vasilieva EV, Clark JF, et al. The creatine kinase system
and cardiomyopathy. Am J Cardiovasc Pathol 1992;4:223–34.
10. Smith SH, Kramer MF, Reis I, Bishop SP, Ingwall JS. Regional
changes in creatine kinase and myocyte size in hypertensive and
nonhypertensive cardiac hypertrophy. Circ Res 1990;67:1334–44.
11. Hugel S, Horn M, De Groot M, et al. Effects of ACE inhibition and
-receptor blockade on energy metabolism in rats postmyocardial
infarction. Am J Physiol 1999;277:H2167–75.
12. Frazier OH, Rose EA, MacMannus Q, et al. Multicenter clinical
evaluation of the Heartmate 1000 IP left ventricular assist device. Ann
Thorac Surg 1992;53:1080–90.
13. Levin HR, Chen JM, Oz MC, et al. Potential of left ventricular assist
devices as outpatient therapy awaiting transplantation. Ann Thorac
Surg 1994;58:1515–20.
14. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins
from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc Natl Acad Sci USA 1979;76:4350–54.
15. Rosalki SB. Improved procedure for serum creatine phosphokinase
determination. J Lab Clin Med 1967;79:696–705.
16. Branwald E, Bristow MR. Congestive heart failure: fifty years of
progress. Circulation 2000;102:IV14–23.
17. Bristow MR, Anderson FL, Port JD, et al. Differences in -adrenergic
neuroeffector mechanism in ischemic versus idiopathic dilated cardio-
myopathy. Circulation 1991;84:1024–39.
18. Sylven C, Lin L, Jansson E, et al. Ventricular adenine nucleotide
translocator mRNA is upregulated in dilated cardiomyopathy. Cardio-
vasc Res 1993;27:1295–9.
19. Fontanet HL, Trask RV, Haas RC, Strauss AW, Abendschein DR,
Billadello JJ. Regulation of expression of M, B, and mitochondrial
creatine kinase mRNAs in the left ventricle after pressure overload in
rats. Circ Res 1991;68:1007–12.
20. Schultz D, Su X, Bishop SP, Billadello J, DellItalia LJ. Selective
induction of the creatine kinase-B gene in chronic volume overload
hypertrophy is not affected by ACE-inhibitor therapy. J Mol Cell
Cardiol 1997;29:2665–73.
21. Saupe KW, Spindler M, Hopkins JC, Shen W, Ingwall JS. Kinetic,
thermodynamic, and developmental consequences of deleting creatine
kinase isoenzymes from the heart. Reaction kinetics of the creatine
kinase isoenzymes in the intact heart. J Biol Chem 2000;275:19742–6.
22. Pauletto P, Nascimben L, Piccolo D, et al. Ventricular myosin and
creatine-kinase isoenzymes in hypertensive rats treated with captopril.
Hypertension 1989;14:556–62.
23. Traverse JH, Melchert P, Pierpont GL, Jones B, Crampton M, Bache
RJ. Impaired myocardial oxygen utilization in the failing heart during
exercise. Circ Res 1999;84:401–8.
24. Hasenfuss G, Mulieri LA, Holubarsch C, Pieske B, Just H, Alpert
NR. Energetics of calcium cycling in nonfailing and failing human
myocardium. Basic Res Cardiol 1992;87:81–92.
25. Ning X-H, Zhang J, Liu J, et al. Signaling and expression for
mitochondrial membrane proteins during left ventricular remodeling
and contractile failure after myocardial infarction. J Am Coll Cardiol
2000;36:282–7.
26. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in
isolated rat hearts. Am J Physiol 1996;270:H1207–16.
27. Mekhfi H, Hoerter J, Lauer C, Wisnewsky C, Schwartz K, Ventura-
Clapier R. Myocardial adaptation to creatine deficiency in rats fed with
beta-guanidinopropionic acid, a creatine analogue. Am J Physiol
1990;258:H1151–8.
28. Saupe KW, Spindler M, Tian R, Ingwall JS. Impaired cardiac
energetics in mice lacking muscle-specific isoenzymes of creatine
kinase. Circ Res 1998;82:898–907.
29. Roman BB, Wieringa B, Koretsky AP. Functional equivalence of
creatine kinase isoforms in mouse skeletal muscle. J Biol Chem
1997;272:17790–4.
30. Portman MA, Ning X-H. Maturational changes in respiratory control
through creatine kinase in heart in vivo. Am J Physiol 1992;263:C453–
60.
31. Murakami Y, Zhang J, Eijgelshoven MH, et al. Myocardial creatine
kinase kinetics in hearts with postinfarction left ventricular remodel-
ing. Am J Physiol 1999;276:H892–900.
1779JACC Vol. 39, No. 11, 2002 Park et al.
June 5, 2002:1773–9 LVAD Effect on Creatine Kinase
